Drug Database · Clinicians

Eperisone

Brands (18) Altavan, Eperib, Eperifer…Show all

Muscle relaxant (centrally acting); Skeletal muscle relaxant PH FDA category

Rx · Prescription drug18 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Hypersensitivity to eperisone
renalcarematters.com, reviewed

Dosing: Adult

  • Muscle tone improvement (neck-shoulder syndrome, low back pain) and spastic paralysis: 150 mg/day in 3 divided doses after meals; adjust for age and symptoms
renalcarematters.com, reviewed

Dosing: Altered kidney function

Eperisone is a centrally acting muscle relaxant with a short half-life (about 1.7 hours). The Japanese package insert contains no kidney-impairment guidance or kidney pharmacokinetic data; it advises dose reduction and caution in older adults. It has no US FDA label.

Kidney function measure: The Japanese package insert does not address kidney impairment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 150 mg/day in 3 divided doses after meals (50 mg three times daily), adjusted for age and symptoms (PMDA insert).
CrCl 30–59 mL/min
The Japanese package insert gives no kidney dosing or kidney pharmacokinetic data. Use with caution and specialist judgment.
CrCl 15–29 mL/min
The Japanese package insert gives no kidney dosing or kidney pharmacokinetic data. Use with caution and specialist judgment.
CrCl <15 mL/min (not on dialysis)
The Japanese package insert gives no kidney dosing or kidney pharmacokinetic data. Use with caution and specialist judgment.
Hemodialysis (intermittent)
Not studied in dialysis; no dose given.
Peritoneal dialysis
Not studied in dialysis; no dose given.
CRRT
Not studied in dialysis; no dose given.
  • Dialyzable? Not stated.
  • Monitoring Weakness, unsteadiness, drowsiness (reduce dose or stop; no driving). Shock, anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis: stop at once. Liver function (may worsen hepatic impairment) (PMDA insert). Proteinuria and raised BUN are listed adverse reactions; check urinalysis and kidney function if symptoms or in CKD.
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: PMDA (Japan) product information (April 2025). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
No pediatric trials (PMDA insert).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 50 mg
  • Tablet: 50 mg

Registered products in the Philippines

18 products registered with the Food and Drug Administration (FDA) Philippines list Eperisone as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Eperisosne Hydrochloride (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products18
Philippine FDA-registered products for Eperisone
Package insert
AltavanEperisone Hydrochloride
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Corbridge Group Phils., Inc.Importer: Pharmakon Biotec Inc.
DRP-15759-05
Sep 11, 2029
EperibEperisone
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Baroque Pharmaceuticals Private LimitedIndia
AMB HK Enterprises Inc.
DRP-18746
Sep 3, 2032
EperiferEperisone Hydrochloride
50 mg Film-Coated TabletAlu / Alu Blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Ferma Drug EnterprisesImporter: Pharmakon Biotec Inc.
DRP-15759-06
Sep 11, 2029
EperilifeEperisone hydrochloride
50 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-16988
Sep 10, 2030
Eperivin-50Eperisone Hydrochloride
50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India 174101
Life And Health Source Pharmaceutical Distribution Co.Importer: Pharmakon Biotec Inc.
DRP-15759-07
Sep 11, 2029
EpertonEperisone hydrochloride
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-16043
Oct 18, 2029
EpizenEperisone hydrochloride
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Kodapharm Med Corp.Importer: Pharmakon Biotec Inc.
DRP-15759-04
Sep 11, 2029
EprelaxEperisone hydrochloride
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15759-02
Sep 11, 2029
GoperisoneEperisone Hydrochloride
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Applied Pharmaceutical Distribution Inc.Importer: Pharmakon Biotec Inc.
DRP-15759-03
Sep 11, 2029
KeersonEperisone hydrochloride
50 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100’s)
Rx
Genom Biotech Pvt. Ltd.India
L’Keeran EnterprisesImporter: Nelpa Lifesciences Inc.
DRP-17754-01
Mar 12, 2031
Laxasaph-GE50Eperisone hydrochloride
50 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box 100's)
Rx
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences Inc.
DRP-17754
Mar 12, 2031
MyelaxEperisone Hydrochloride
50 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
Myungmoon Pharm. Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.
DR-XY43367
Apr 28, 2029
MyonalEperisone Hydrochloride
50 mg TabletClear PVC/Aluminum Foil Blister Strip x 10's (Box of 100's)
Rx
Swiss Pharma Research Laboratories, Inc.Laguna
DKSH Market Expansion Services Philippines, Inc.Trader: Favorex Pte. Ltd.
DR-XY22030
Oct 16, 2036
MyorexEperisosne HydrochlorideVariant spelling
50 mg Film-Coated TabletAlu/Alu blister pack x 10’s (Box of 100’s and 30's)
Rx
Magbro Healthcare Pvt. Ltd.India
D'Conner PharmaImporter: Teramedix Pharma Trading Inc.
DRP-16043-02
Oct 18, 2029
PerispaEperisone Hydrochloride
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Platinum Pharmaceuticals (Pvt.) Ltd.Pakistan
Wert Philippines, Inc.
DR-XY35442
Feb 11, 2027
ReduspasmEperisone hydrochloride
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc..
DRP-15759
Sep 11, 2029
RetalaxEperisone Hydrochloride
50 mg Film-Coated tabletAlu-Alu Blister Pack x 10's (Box of 100’s)
Rx
Magbro Healthcare Pvt. LtdIndia 174101
Reta DrugImporter: Teramedix Pharma Trading Inc.
DRP-16043-01
Oct 18, 2029
SpasmirEperisone hydrochloride
50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15759-01
Sep 11, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
MethocarbamolAdjust or monitorEye accommodation disorder reported with the related drug tolperisone.Use with caution.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Weakness, unsteadiness, drowsiness
  • Proteinuria, raised BUN (frequency not stated)

Serious

  • Shock, anaphylaxis
  • Toxic epidermal necrolysis, Stevens-Johnson syndrome
renalcarematters.com, reviewed

Monitoring parameters

  • Weakness, unsteadiness, drowsiness (reduce dose or stop; no driving). Shock, anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis: stop at once. Liver function (may worsen hepatic impairment) (PMDA insert). Proteinuria and raised BUN are listed adverse reactions; check urinalysis and kidney function if symptoms or in CKD. Kidney
  • Sedation and weakness; liver function in hepatic impairment
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peak1.6 to 1.9 hours
Half-life1.6 to 1.8 hours
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Eperisone Hydrochloride 50 mg Tablet₱4.29–₱29.00Reference ₱11.50per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Eperisone hydrochloride
PNF listingOral: 50 mg tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Pharmaceuticals and Medical Devices Agency (Japan). Myonal tablets 50 mg / granules 10% package insert [PMDA (Japan) product information, April 2025; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987028511113
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Myonal tablets 50 mg and granules 10% (eperisone hydrochloride) [Japanese package insert, 2nd edition, revised April 2025; drug-information contact: Kaken Pharmaceutical Co., Ltd.]. (2025). Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987028511113

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .